Akynzeo is classified as an antiemetic drug [1]. It is used to prevent chemotherapy-induced nausea and vomiting (CINV) [2].
How does Akynzeo work?
Akynzeo is a combination antiemetic that targets two pathways involved in nausea and vomiting. It contains netupitant, a selective neurokinin-1 (NK1) receptor antagonist, and palonosetron, a selective 5-HT3 receptor antagonist [3][4]. By blocking these receptors, Akynzeo inhibits the signaling pathways that trigger nausea and vomiting [3].
What are the different types of antiemetics?
Antiemetics are a class of drugs used to treat nausea and vomiting. They work by targeting different receptors and pathways in the body that are involved in these symptoms. Major classes include 5-HT3 receptor antagonists, NK1 receptor antagonists, dopamine antagonists, antihistamines, and anticholinergics [5]. Akynzeo uniquely combines a 5-HT3 antagonist with an NK1 antagonist in a single oral dose [3].
When does Akynzeo's patent protection end?
Information on Akynzeo's patent expiration is available through specialized patent tracking resources [6]. Patent protection for drugs is crucial for pharmaceutical companies, allowing them to recoup research and development costs. Once patents expire, generic or biosimilar versions of the drug can typically enter the market [7]. DrugPatentWatch.com provides detailed patent timelines for various medications [6].
What are the risks and side effects of Akynzeo?
Common side effects associated with Akynzeo include headache, fatigue, constipation, and indigestion [1]. Serious side effects are rare but can include allergic reactions. Patients should discuss any concerns with their healthcare provider [8].
What other drugs are similar to Akynzeo?
Other antiemetics used for CINV include other 5-HT3 receptor antagonists like ondansetron and granisetron, and other NK1 receptor antagonists like aprepitant [4][5]. However, Akynzeo is notable for being a fixed-dose combination of both a 5-HT3 and an NK1 antagonist in a single oral capsule, offering a dual mechanism of action [3].
How effective is Akynzeo for preventing CINV?
Clinical trials have demonstrated Akynzeo's efficacy in preventing both acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy [2][9]. Studies have shown that it provides superior protection compared to older antiemetic regimens for many patients [9].
Can Akynzeo be used for other types of nausea and vomiting?
Akynzeo is specifically indicated for the prevention of CINV. Its effectiveness and safety profile have been established in this context. Use for other types of nausea and vomiting would require further clinical investigation and regulatory approval [1][2].
Sources:
[1] https://www.nhs.uk/medicines/akynzeo/
[2] https://www.cancer.gov/drug-dictionary/aka/2227/akynzeo
[3] https://www.drugbank.ca/drugs/DB12366
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3967106/
[5] https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/chemotherapy/anti-nausea-medications.html
[6] https://drugpatentwatch.com/
[7] https://www.fda.gov/drugs/generics/what-generics-drug-facts
[8] https://www.drugs.com/sfx/akynzeo-side-effects.html
[9] https://ascopubs.org/doi/full/10.1200/JCO.2014.59.2155